IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression

Journal of Biological Chemistry

Volumn 288, Issue 18, 2013, Pages 12569-12573

  Samanta, Sanjoy ^a   Pursell, Bryan ^a   Mercurio, Arthur M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; BREAST CANCER RESISTANCE PROTEINS; CHEMORESISTANCE; CLINICAL MANAGEMENT; INSULIN-LIKE GROWTH FACTOR; MRNA-BINDING PROTEIN; TRIPLE-NEGATIVE BREAST CANCERS;

CELLS; PROTEINS;

DISEASES;

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; INSULIN LIKE GROWTH FACTOR 2 MESSENGER RNA BINDING PROTEIN 3; MESSENGER RNA; MITOXANTRONE; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTEIN TARGETING;

BREAST CANCER; CHEMORESISTANCE; DRUG TRANSPORT; MRNA; RNA-BINDING PROTEIN;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; PROTEIN BINDING; RNA, MESSENGER; RNA, NEOPLASM; RNA-BINDING PROTEINS;

EID: 84877143619     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.C112.442319     Document Type: Article

References (17)

1. Mueller-Pillasch, F., Pohl, B., Wilda, M., Lacher, U., Beil, M., Wallrapp, C., Hameister, H., Knöchel, W., Adler, G., and Gress, T. M. (1999) Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. 88, 95-99 (Pubitemid 29467415)
2. Walter, O., Prasad, M., Lu, S., Quinlan, R. M., Edmiston, K. L., and Khan, A. (2009) IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum. Pathol. 40, 1528-1533
3. Griffiths, C. L., and Olin, J. L. (2012) Triple negative breast cancer: a brief review of its characteristics and treatment options. J. Pharm. Pract. 25, 319-323
4. Turner, N., Tutt, A., and Ashworth, A. (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (Pubitemid 39331153)
5. Doyle, L. A., and Ross, D. D. (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358 (Pubitemid 37487163)
6. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
7. Liao, B., Hu, Y., Herrick, D. J., and Brewer, G. (2005) The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem. 280, 18517-18524 (Pubitemid 41389102)
8. Ibrahim, N. K., Buzdar, A. U., Asmar, L., Theriault, R. L., and Hortobagyi, G. N. (2000) Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann. Oncol. 11, 1597-1601 (Pubitemid 32104760)
9. Petit, T., Borel, C., Theobald, S., Serin, D., Rodier, J. F., Prevot, G., Brettes, J. P., and Klein, T. (2003) Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. Ann. Surg. Oncol. 10, 369-375 (Pubitemid 40486933)
10. Rowinsky, E. K., Onetto, N., Canetta, R. M., and Arbuck, S. G. (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19, 646-662 (Pubitemid 23004842)
11. Hazlehurst, L. A., Foley, N. E., Gleason-Guzman, M. C., Hacker, M. P., Cress, A. E., Greenberger, L. W., De Jong, M. C., and Dalton, W. S. (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 59, 1021-1028 (Pubitemid 29135961)
12. Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T. A., Runge, S., Risbood, M., Poruchynsky, M. S., and Bates, S. E. (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89, 1971-1978 (Pubitemid 37533279)
13. Sharom, F. J. (2008) ABC multidrug transporters: structure, function, and role in chemoresistance. Pharmacogenomics 9, 105-127
14. Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., and Nielsen, F. C. (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell. Biol. 19, 1262-1270 (Pubitemid 29046868)
15. Jiang, Z., Chu, P. G., Woda, B. A., Rock, K. L., Liu, Q., Hsieh, C. C., Li, C., Chen, W., Duan, H. O., McDougal, S., and Wu, C. L. (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 7, 556-564 (Pubitemid 43923666)
16. Ikeda, K., Tate, G., Suzuki, T., Kitamura, T., and Mitsuya, T. (2011) Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn. Cytopathol. 39, 395-401
17. Janiszewska, M., Suvà, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J., Clément-Schatlo, V., Radovanovic, I., Rheinbay, E., Provero, P., and Stamenkovic, I. (2012) Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 26, 1926-1944